Drug Trial Radar · NCT03872947
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
138
Actual
Start
Apr 26, 2019
Primary completion
Jul 16, 2026
Study completion Jul 16, 2026
Sponsor
- Lead sponsor
- Toray Industries, IncIndustry
- Sponsor type
- Industry
- First posted
- Mar 13, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to establish the safety and the recommended dose of TRK-950 in combination with FOLFIRI, Gemcitabine / Cisplatin, Gemcitabine / Carboplatin, Ramucirumab / Paclitaxel, PD1 inhibitors (Nivolumab or Pembrolizumab), and Imiquimod Cream, Bevacizumab, Gemcitabine / Carboplatin / Bevacizumab, Pegylated liposomal doxorubicin (PLD), Carboplatin / PLD / Bevacizumab and Paclitaxel for selected advanced solid tumors.
Conditions
- Solid Tumor
- Colorectal Cancer
- Cholangiocarcinoma
- Bladder Cancer
- Ovarian Cancer
- Gastric Cancer
- Palpable Subcutaneous Malignant Lesions
- Renal Cell Carcinoma
- Melanoma
- Epithelial Ovarian Cancer
- Primary Peritoneal Cancer
- Fallopian Tube Cancer
Interventions
TRK-950Biological
10 mg/kg administered intravenously over 60 minutes (weekly)
TRK-950Biological
5 mg/kg administered intravenously over 60 minutes (weekly)
TRK-950Biological
Treatment Phase: 20 mg/kg administered intravenously over 60 minutes (bi-weekly) Maintenance Phase: 30 mg/kg administered intravenously over 60 minutes (every 3 weeks)
IrinotecanDrug
Intravenously over 30 - 90 minutes
LeucovorinDrug
Intravenously over 30 - 90 minutes
5-FUDrug
Intravenously bolus and intravenously for two days
GemcitabineDrug
Intravenously over 30 minutes
CisplatinDrug
Intravenously over 60 minutes
CarboplatinDrug
Intravenously per package insert
RamucirumabDrug
Intravenously over 60 minutes
PaclitaxelDrug
Intravenously
NivolumabDrug
Intravenously over 30 minutes
PembrolizumabDrug
Intravenously over 30 minutes
Imiquimod CreamDrug
Topically
BevacizumabDrug
Intravenously over 90 minutes for the first dose, over 60 for the second dose and over 30 minutes for all subsequent doses
PLDDrug
Intravenously over 60 minutes
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of patients experiencing treatment emergent adverse events as assessed by CTCAE v5.0Time frame: through study completion, an average of 1 year
- Frequency of patients experiencing adverse events of special interest (AESIs)Time frame: through study completion, an average of 1 year
- Blood pressureTime frame: through study completion, an average of 1 year
- Heart rateTime frame: through study completion, an average of 1 year
- Respiratory rateTime frame: through study completion, an average of 1 year
- TemperatureTime frame: through study completion, an average of 1 year
- WeightTime frame: through study completion, an average of 1 year
- HeightTime frame: through study completion, an average of 1 year
- Performance status using Karnofsky performance status criteriaTime frame: through study completion, an average of 1 year
- QTc interval determined from 12-lead ElectrocardiogramTime frame: through study completion, an average of 1 year
- QRS interval determined from 12-lead ElectrocardiogramTime frame: through study completion, an average of 1 year
- Frequency of patients with laboratory abnormalities (Complete Blood Count, Coagulation, Urinalysis and Serum Chemistry)Time frame: through study completion, an average of 1 year
Locations
14 sites in 2 countries. Site status is shown where the registry gives one.
HonorHealth Research Institute
Scottsdale, Arizona
AOA-HOPE
Tucson, Arizona
USC Norris Comprehensive Cancer Center
Los Angeles, California
HOAG Memorial Hospital Presbyterian
Newport, California
Ochsner Clinic Foundation
New Orleans, Louisiana
Atlantic Health System
Morristown, New Jersey
Perlmutter Cancer Center at NYU Langone
New York, New York
Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute and Research Center)
Eugene, Oregon
Northwest Cancer Specialists
Portland, Oregon
Texas Oncology, P.A. Baylor Charles A. Sammons Cancer Center
Dallas, Texas
Texas Oncology - Downtown Fort Worth Cancer Center
Fort Worth, Texas
Virginia Cancer Specialists, PC
Leesburg, Virginia
Medical College of Wisconsin
Milwaukee, Wisconsin
Centre Léon Bérard
Lyon, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.